Skinner Charles M, Nookaew Intawat, Ewing Laura E, Wongsurawat Thidathip, Jenjaroenpun Piroon, Quick Charles M, Yee Eric U, Piccolo Brian D, ElSohly Mahmoud, Walker Larry A, Gurley Bill, Koturbash Igor
Center for Dietary Supplements Research, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Department of Environmental and Occupational Health, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
J Diet Suppl. 2020;17(5):543-560. doi: 10.1080/19390211.2020.1761506. Epub 2020 May 13.
Cannabidiol (CBD) is the major non-psychotropic phytocannabinoid present in . In 2018, Congress designated certain plant material as "hemp," thus removing it from the DEA's list of controlled substances. As a result, CBD-containing hemp extracts and other CBD products are now widely available and heavily marketed, yet their FDA regulatory status is still hotly debated. The goal of this study was to investigate the effects of a cannabidiol-rich cannabis extract (CRCE) on the gut microbiome and associated histomorphological and molecular changes in the mouse gut mucosa. Male C57BL6/J mice were gavaged with either 0, 61.5, 184.5, or 615mg/kg/bw of CRCE in sesame oil for 2weeks (Mon-Fri). Substantial CRCE-induced increases in the relative abundance of , a bacterial species currently accepted as probiotic, was observed in fecal samples at all doses. This was paralleled by decreases in the relative abundance of other gut bacterial species. Coincident with the observed changes in gut ecology were multiple pro-inflammatory responses, including increased expression of cytokines and chemokines-, , and in the colon tissue. Furthermore, dramatic increases in the relative abundance of significantly decreased expression of a gene intimately associated with gut integrity. Taken together, these findings raise concerns about the safety of long-term CBD usage and underline the need for additional well-designed studies into its tolerability and efficacy.
大麻二酚(CBD)是 中主要的非精神活性植物大麻素。2018年,国会将某些 植物材料指定为“大麻”,从而将其从美国缉毒局的受控物质清单中删除。因此,含CBD的大麻提取物和其他CBD产品现在广泛可得且大量销售,但其在美国食品药品监督管理局(FDA)的监管地位仍备受争议。本研究的目的是调查富含大麻二酚的大麻提取物(CRCE)对肠道微生物群以及小鼠肠道黏膜相关组织形态学和分子变化的影响。雄性C57BL6/J小鼠连续2周(周一至周五)每天经口灌胃给予0、61.5、184.5或615mg/kg体重的CRCE(溶于芝麻油中)。在所有剂量下,粪便样本中均观察到CRCE显著诱导目前被视为益生菌的一种细菌物种的相对丰度增加。与此同时,其他肠道细菌物种的相对丰度下降。与观察到的肠道生态变化同时出现的是多种促炎反应,包括结肠组织中细胞因子和趋化因子( 、 和 )表达增加。此外, 相对丰度的显著增加显著降低了与肠道完整性密切相关的一个基因的表达。综上所述,这些发现引发了对长期使用CBD安全性的担忧,并强调需要进行更多精心设计的研究来探讨其耐受性和疗效。